OncoCyte (OCX) Upgraded to “Buy” by Zacks Investment Research

Zacks Investment Research upgraded shares of OncoCyte (NYSEAMERICAN:OCX) from a hold rating to a buy rating in a report published on Saturday morning. They currently have $4.75 price objective on the biotechnology company’s stock.

According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “

Separately, ValuEngine downgraded OncoCyte from a hold rating to a sell rating in a research note on Thursday, October 5th.

OncoCyte (NYSEAMERICAN:OCX) traded up $0.05 during trading on Friday, reaching $4.30. The company’s stock had a trading volume of 7,170 shares, compared to its average volume of 30,713. The stock has a market cap of $135.14 and a P/E ratio of -6.94. OncoCyte has a twelve month low of $3.60 and a twelve month high of $7.85.

An institutional investor recently raised its position in OncoCyte stock. Broadwood Capital Inc. lifted its stake in OncoCyte Co. (NYSEAMERICAN:OCX) by 17.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,596,680 shares of the biotechnology company’s stock after buying an additional 540,000 shares during the quarter. OncoCyte makes up 4.5% of Broadwood Capital Inc.’s holdings, making the stock its 5th largest position. Broadwood Capital Inc. owned about 11.48% of OncoCyte worth $27,155,000 as of its most recent filing with the Securities & Exchange Commission.

TRADEMARK VIOLATION WARNING: “OncoCyte (OCX) Upgraded to “Buy” by Zacks Investment Research” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/14/oncocyte-ocx-upgraded-to-buy-by-zacks-investment-research.html.

OncoCyte Company Profile

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply